12 February – Webinar in connection with year-end report
Alligator hosted a webinar and conference call for investors, analysts where CEO Søren Bregenholt and CFO Johan Giléus presented and commented on the 2025 year-end report. The presentation was followed by a Q&A session.
The recording can be requested via >> this link <<.
19 August – R&D event
Alligator hosted a virtual R&D Day on Tuesday, 19 August 2025 providing an in-depth update on Alligator’s R&D pipeline, with a primary focus on its lead candidate mitazalimab, ahead of the upcoming TO 13 warrant exercise period (1–15 September 2025).
LATEST NEWS
Change in number of shares and votes in Alligator Bioscience AB
During March 2026, the number of shares and votes in Alligator Bioscience AB (“Alligator Bioscience”) has increased as a result …
Notice of annual general meeting in Alligator Bioscience AB
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis …
The Nomination Committee’s proposals regarding the Board of Directors for the Annual General Meeting in Alligator Bioscience AB (publ)
The Nomination Committee of Alligator Bioscience AB (publ) (“Alligator Bioscience”) proposes re-election of Hans-Peter Ostler an …